
“RDY Q3 Earnings Meet Expectations as Generics Revenues Increase Year-Over-Year, But Stock Declines: A Comprehensive Analysis”
Dr. Reddy’s Stock Falls on Q3 Fiscal 2025 Results The Numbers In the latest earnings report for Q3 fiscal 2025, Dr. Reddy’s Laboratories faced a downturn in stock value as the numbers were released. While the earnings matched estimates, it was the revenues that exceeded expectations. This led to a mixed reaction from investors, resulting…